Medical/Pharmaceuticals
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the U.S. Food an...
2023-03-29 14:00
3168
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. * The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in p...
2023-03-29 08:30
2455
Innovent Announces 2022 Annual Results and Business Updates
Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer...
2023-03-29 08:00
3317
Verbal Beginnings partners with The Clinician to launch a Patient Reported Outcomes Program for Children with Autism Spectrum Disorder
COLUMBIA, Md., March 29, 2023 /PRNewswire/ -- A leading US-based Applied
Behavior Analysis (ABA) therapy provider
2023-03-29 02:32
1974
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022. 1. Sales Revenue Reached 5.6 Times Year-Over-Year ...
2023-03-28 21:40
2503
BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO
Acquisition expands Bimini's global soft tissue franchise, which already includes the PureGraft and Dermapose Fat Transfer Systems PLANO, Texas, March 28, 2023 /PRNewswire/ -- Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology...
2023-03-28 21:20
1575
New Study Reveals Clinical Instability Predicts Psychiatric Hospitalization
First study of its kind, based on real-world data from Holmusk's NeuroBlu Database, shows patients who score highest for severity and instability were 45% more likely to be hospitalized NEW YORK, March 28, 2023 /PRNewswire/ -- For patients with psychiatric conditions, illness severity and i...
2023-03-28 21:00
2124
Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment
SHANGHAI, March 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the results from its PADN series study during the Late-Breaking Clinical Science (LBCS) session of the second Technology and Heart Failure Therapeutics (THT 2023), with the presentatio...
2023-03-28 20:30
1737
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval ...
2023-03-28 20:11
2234
Sirnaomics Announces 2022 Annual Results
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights * Clinical development * STP705 - The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with th...
2023-03-28 19:26
6936
Seegene declares to share Syndromic PCR technologies to prevent future pandemics
* Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands. * Formation of a collaborative global network to aggressively develop innovative syndromic PCR assays, challenging boundaries of PCR application....
2023-03-28 19:00
1899
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on...
2023-03-28 19:00
1551
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
SINGAPORE, March 28, 2023 /PRNewswire/ -- Becton Dickinson Holdings Pte Ltd (BD), a global leader in life science technologies, and the Agency for Science, Technology and Research (A*STAR),Singapore's lead public sector R&D agency, have announced an extended research partnership that will focus o...
2023-03-28 14:12
1928
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
Tavneos® newly introduced in the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV) Recommendations recognize Tavneos®' ability to induce and sustain remission, lower glucocorticoids-induced toxic effects and pot...
2023-03-28 13:00
2315
HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR
SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing novel immunotherapies for multiple myeloma, today announced that its anti-KMA CAR-T cell preclinical development has been completed and is the subject of an abstract accepted for poster presentation...
2023-03-28 09:43
1894
BioDuro-Sundia Announces Formation of Scientific Advisory Board
IRVINE, Calif., March 28, 2023 /PRNewswire/ -- BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas...
2023-03-28 08:30
2607
Boan Biotech Announces 2022 Financial Results
Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2022 financial results and recent business developments. 2022 business highlights * Record high in revenue: In 2022, Boan Biotech's revenue was...
2023-03-27 23:15
3930
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
* The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing antibody against Omicron virus on Day 14, with statistical significance (95%CI: 2.1, 3.4, P<0.0001) based on interim data analysis * The tr...
2023-03-27 18:00
1821
Noul Co. Ltd - The RIGHT Foundation Commences Research and Development for Supporting Malaria Control
* Aim to accelerate global business and access to the public market based on reliable research results YONGIN, South Korea, March 27, 2023 /PRNewswire/ -- Noul Co. Ltd (CEO :David Lim) announced that it has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to de...
2023-03-27 17:34
1789
Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves
SHANGHAI, March 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that it has received full u...
2023-03-27 08:15
2361
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 298 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 279 media titles]
2024-11-29 20:33
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
6075
Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
2024-11-26 13:00
5154